Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 10;52(6):2096–2105. doi: 10.1161/STROKEAHA.120.030565

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Portola Pharmaceuticals Inc, a subsidiary of Alexion Pharmaceuticals Inc, and the Authors.

Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Subgroup analysis of patients achieving excellent or good hemostasis 12 h after andexanet treatment. Spontaneous (A) and traumatic (B) ICrH populations reported separately. *Evaluable patients. In A, 1 patient from the efficacy cohort of 99 patients was not evaluable. In B, 2 patients from the efficacy cohort of 72 patients were not evaluable. Sizes of squares indicate relative numbers of patients. ICH indicates intracerebral hemorrhage; ICrH, intracranial hemorrhage; IVH, intraventricular hemorrhage; SAH, subarachnoid hemorrhage; and SDH, subdural hemorrhage.